PepGen Inc.PEPG
...Loading PEPG Peers...
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
76 Employees
CEO : Dr. James G. McArthur Ph.D.
Address : 245 Main Street, Cambridge,MA, US, - 02142,
| Key Excutives | Designation |
|---|---|
| Mr. Noel P. Donnelly M.B.A. | Chief Financial Officer |
| Dr. Michael Gait Ph.D. | Founder & Scientific Advisory Board Member |
| Mr. David E. Borah C.F.A., M.B.A. | Senior Vice President of IR & Corporate Communications |
| Mr. Niels Svenstrup Ph.D. | Senior Vice President of Biological Chemistry |
| Ms. Emiko Bryant | Chief of Staff |
| Dr. Hayley Parker Ph.D. | Senior Vice President of Global Regulatory Affairs |
| Dr. Michelle L. Mellion M.D. | Chief Medical Officer |
| Dr. James G. McArthur Ph.D. | President, Chief Executive Officer, Treasurer, Secretary & Director |
| Ms. Mary Beth DeLena J.D. | General Counsel & Secretary |
| Dr. Afsaneh Mohebbi Ph.D. | Senior Vice President of Portfolio and Program Management |